Author:
Qayyum Aliya,Hwang Ken-Pin,Stafford Jason,Verma Anuj,Maru Dipen M.,Sandesh Subramanya,Sun Jia,Pestana Roberto Carmagnani,Avritscher Rony,Hassan Manal M.,Amin Hesham,Rashid Asif,Wistuba Ignacio I.,Ehman Richard L.,Ma Jingfei,Kaseb Ahmed O.
Subject
Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy
Reference17 articles.
1. Mlynarsky L, Menachem Y, Shibolet O. Treatment of hepatocellular carcinoma: Steps forward but still a long way to go. World J Hepatol. 2015;7(3):566–74.
2. Osaki Y, Nishikawa H. Treatment of hepatocellular carcinoma in Japan over the last three decades: our experience and published work review. Hepatol Res. 2015;45:59–74.
3. Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nature Rev. 2015;12(7):408–24.
4. Redman JM, Hill EM, AlDeghaither D, Weiner LM. Mechanisms of action of therapeutic antibodies for cancer. Mol Immunol. 2015;67(2, Part A):28–45.
5. Terme M, Ullrich E, Aymeric L, et al. IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res. 2011;16:5393–9.
https://doi.org/10.1158/0008-5472.CAN-11-0993
PMID: 21724589.
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献